FMP
XOMA Corporation
XOMA
NASDAQ
XOMA Corporation operates as a biotechnology royalty aggregator in Europe, the United States, and the Asia Pacific. The company engages in helping biotech companies for enhancing human health. It acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. The company focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners. It has a portfolio with approximately 70 assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.
18.76 USD
-0.47 (-2.51%)
Operating Data
Year
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
Revenue
29.39M
38.16M
6.03M
4.76M
28.49M
30.24M
32.1M
34.07M
36.17M
38.39M
Revenue %
-
29.86
-84.21
-21.06
498.72
6.15
6.15
6.15
6.15
Ebitda
13.81M
16.52M
-16.84M
-39.36M
-5.42M
-7.79M
-8.27M
-8.77M
-9.31M
-9.89M
Ebitda %
47.01
43.28
-279.49
-827.28
-19.04
-25.75
-25.75
-25.75
-25.75
Ebit
13.64M
16.35M
-17.12M
-40.26M
-5.64M
-7.89M
-8.38M
-8.89M
-9.44M
-10.02M
Ebit %
46.42
42.85
-284.04
-846.2
-19.79
-26.11
-26.11
-26.11
-26.11
Depreciation
172k
167k
274k
900k
216k
1.53M
1.62M
1.72M
1.83M
1.94M
Depreciation %
0.59
0.44
4.55
18.92
0.76
5.05
5.05
5.05
5.05
EBIT (Operating profit)(Operating income)(Operating earning) = GROSS MARGIN (REVENUE - COGS) - OPERATING EXPENSES (R&D, RENT) EBIT = (1*) (2*) -> operating process (leverage -> interest -> EBT -> tax -> net Income) EBITDA = GROSS MARGIN (REVENUE - COGS) - OPERATING EXPENSES (R&D, RENT) + Depreciation + amortization EBITA = (1*) (2*) (3*) (4*) company's CURRENT operating profitability (i.e., how much profit it makes with its present assets and its operations on the products it produces and sells, as well as providing a proxy for cash flow) -> performance of a company (1*) discounting the effects of interest payments from different forms of financing (by ignoring interest payments), (2*) political jurisdictions (by ignoring tax), collections of assets (by ignoring depreciation of assets), and different takeover histories (by ignoring amortization often stemming from goodwill) (3*) collections of assets (by ignoring depreciation of assets) (4*) different takeover histories (by ignoring amortization often stemming from goodwill)
